DPX-Survivac and Checkpoint Inhibitor in DLBCL

Model scores of the 29,894 trials active now.

Model score 23% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-07-18. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: celllymphomastemtransplantwilling
  Phrases that lowered it: combinationlineparticipantsdrugsdiseases
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 9.4% (raises risk) · Sponsor's track record
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 47 (lowers risk) · Sponsor's track record
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Keywords listed: 36 (raises risk) · Design
• Drug's FAERS reports with a death: 24.7% (raises risk) · Drug's FDA history
• Collaborators: 2 (lowers risk) · Design
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 80819 (lowers risk) · Drug's FDA history
• Sponsor's past trials: 128 (lowers risk) · Sponsor's track record
• Drug's FAERS reports in the prior 12 months: 17515 (lowers risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 92.5% (raises risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL NCT03305445 · started 2018 · scored riskier than 84% of active trials completed
• Sequential Intranodal Immunotherapy (SIIT) Combined With Anti-PD1 (Pembrolizumab) in Follicular Lymphoma NCT02677155 · started 2016 · scored riskier than 56% of active trials completed
• Pembrolizumab for Patients With PD-L1 Diffuse Large B Cell Lymphoma (DLBCL) NCT03990961 · started 2019 · scored riskier than 76% of active trials terminated
• RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy NCT04827862 · started 2022 · scored riskier than 85% of active trials completed
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma NCT03401853 · started 2018 · scored riskier than 54% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.